As per the report published, the size of the European Veterinary/Animal Vaccines Market is poised to reach USD 2.98 Billion by 2025 from USD 2.34 Billion in 2020, at a CAGR of 4.97% from 2020 to 2025.
Vaccination protects animals from specific infectious diseases and may be carried out either routinely or potentially in an emergency. Immunization of animals used for food can also help protect consumers against zoonotic pathogens such as salmonella.
The European Veterinary/Animal vaccine market is as old as the concept itself, and the newest products are significantly available throughout the market. The farmers and animal husbandry owners seem well versed in the idea of animal vaccination. But the real test lies in the stringent guidelines for animal vaccines testing as per EU regulations. It prevents or at least hardens the route for new players to enter the market. Also, the market has undergone considerable progress during the past few years with the growing usage of continuous cell lines as a substrate and embracing of the fermentor technology for antigen production. These vaccines are produced for administration by parenteral or oral routes depending on the vaccine characteristics.
Growing prevalence of animal diseases, rising incidences of zoonotic diseases in humans, increasing investments by leading players, various government agencies, and animal associations; continuous innovations; raising awareness against the use of antimicrobials is driving the vaccine producers to invest significantly into development of new products.
However, rising maintenance costs for the storage of vaccines, increasing adoption of a vegetarian diet in major economies owing to the increased risk of obesity and other chronic diseases are key restraints of this market.
France Veterinary Vaccines Market
Players in France are manufacturing veterinary vaccines according to the requirements of the European pharmacopeia & OIE norms with specific needs. Vaccine manufacturers are using purified recombinant proteins for vaccination to identify the target. Increasing awareness of zoonotic diseases is a significant contributor to the France veterinary vaccine market. Rising healthcare facilities and infrastructure show a positive impact on the veterinary vaccine and related products in France. The key players of France veterinary vaccine market are Boehringer Ingelheim, Zoetis Inc., and Bayer Healthcare.
Italy Veterinary Vaccines Market
Italy is holding dominant shares of the market following France by owing to the rising number of infectious diseases. Rising awareness about animal health and vaccines will drive the veterinary vaccines market. The Italian veterinary healthcare market developed animal therapeutic products to grow the market. Italy dominated by the export & business investment market. It will open lucrative business opportunities to the key companies to increase their demand in the Italian veterinary vaccines market.
This research report segmented and sub-segmented into the following categories:
Based on technology, the canine vaccines segment accounted for a slightly larger share (in terms of revenue) than the feline vaccines segment, due to higher average cost allied with canine vaccination.
Regionally, the European region is leading the Global Veterinary/Animal Vaccines Market in terms of consumption.
Prominent companies playing an active role in the Europe Veterinary/Animal Vaccines Market are Bayer HealthCare AG, Bioniche Animal Health Canada, Sanofi Animal Health. Inc., Biogenesis Bago SA, Heska Corporation, Indian Immunologicals Ltd., Boehringer Ingelheim GmbH, Zoetis, Novartis Animal Health. Inc., Merck & Co. Inc., and Protein Sciences.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.2 Analysis Design
2.3 Research Phases
2.3.1 Secondary Research
2.3.2 Primary Research
2.3.3 Econometric Modelling
2.3.4 Expert Validation
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Type
5.1.1 Livestock vaccines
5.1.2 Companion vaccines
5.2.1 Live attenuated vaccines
5.2.2 Inactivated vaccines
5.2.3 Recombinant vaccines
5.2.4 Toxoid vaccines
5.2.5 Subunit vaccines
5.2.6 DNA vaccines
5.2.7 Conjugate vaccines
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Bayer Healthcare AG
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Bioniche Animal Health Canada
8.3 Sanofi Animal Health Inc.
8.4 Biogenesis Bago SA
8.5 Heska Corporation
8.6 Indian Immunologicals Ltd.
8.7 Boehringer Ingelheim GmbH
8.8 Novartis Animal Health, Inc.
8.9 Merck & Co. Inc.
8.10 Protein Sciences
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities